N-亚硝基三(2-氯乙基)碳酰二胺 | 69113-01-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-亚硝基三(2-氯乙基)碳酰二胺
• 中文别名: N-亚硝基三-(2-氯乙基)脲
• 英文名称: Urea, 1-nitroso-1,3,3-tris(2-chloroethyl)-
• 英文别名: 1,1,3-tris(2-chloroethyl)-3-nitrosourea
• CAS: 69113-01-5
• 化学式: C₇H₁₂Cl₃N₃O₂
• 分子量: 276.5
• InChiKey: KIRNCVMRJCUYPS-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±52.0 °C(Predicted)
• 密度：
  1.8000 (rough estimate)
• 溶解度：
  可溶于氯仿（少量）、乙酸乙酯（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  53
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
  申请人：Trustees of Boston University

  公开号：US10927417B2

  公开（公告）日：2021-02-23

  Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

  本文公开了用于鉴定恶性肿瘤前期病变的检测方法和方法，以及确定此类恶性肿瘤前期病变发展为肺癌的可能性的方法。还公开了用于监测恶性前病变向肺癌发展的方法和测定。本文公开的检测方法提供了准确检测和监测恶性肿瘤前期病变存在与否的微创手段，从而为肺癌的早期阶段提供了新的见解，有利于早期检测和早期干预。
• METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION
  申请人：Trustees of Boston University

  公开号：EP3840634A1

  公开（公告）日：2021-06-30
• Protein Kinase C Iota
  申请人：Fields P. Alan

  公开号：US20070283451A1

  公开（公告）日：2007-12-06

  The invention involves PKCι signaling. The invention provides, for example, transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer.
• PROTEIN KINASE C IOTA
  申请人：Fields Alan P.

  公开号：US20100092578A1

  公开（公告）日：2010-04-15

  The invention involves PKC ι signaling. The invention provides, for example, transgenic animals, inhibitors of PKC ι signaling, methods for inhibiting PKC ι signaling, methods for identifying inhibitors of PKC ι signaling, and methods for diagnosing cancer.
• GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS
  申请人：Trustees of Boston University

  公开号：US20180010197A1

  公开（公告）日：2018-01-11

  Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.